Leman Yel

3.5k total citations
76 papers, 2.5k citations indexed

About

Leman Yel is a scholar working on Immunology, Hematology and Genetics. According to data from OpenAlex, Leman Yel has authored 76 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Immunology, 36 papers in Hematology and 21 papers in Genetics. Recurrent topics in Leman Yel's work include Immunodeficiency and Autoimmune Disorders (44 papers), Platelet Disorders and Treatments (26 papers) and Blood disorders and treatments (19 papers). Leman Yel is often cited by papers focused on Immunodeficiency and Autoimmune Disorders (44 papers), Platelet Disorders and Treatments (26 papers) and Blood disorders and treatments (19 papers). Leman Yel collaborates with scholars based in United States, Türkiye and Japan. Leman Yel's co-authors include Sudhir Gupta, Hans D. Ochs, Wen-I Lee, Sastry Gollapudi, Shigeaki Nonoyama, Nadia Catalan, Bodil Kavli, Alain Fischer, Hans E. Krokan and Kohsuke Imai and has published in prestigious journals such as New England Journal of Medicine, Blood and Nature Immunology.

In The Last Decade

Leman Yel

72 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Leman Yel United States	23	1.6k	592	499	445	359	76	2.5k
Andrea Finocchi Italy	24	886 0.5×	505 0.9×	286 0.6×	154 0.3×	330 0.9×	84	1.8k
Neal S. Rote United States	39	1.2k 0.8×	753 1.3×	307 0.6×	640 1.4×	466 1.3×	113	4.1k
Αthanasia Mouzaki Greece	30	932 0.6×	659 1.1×	202 0.4×	461 1.0×	514 1.4×	128	2.8k
Paul Hasler Switzerland	27	2.0k 1.2×	772 1.3×	251 0.5×	191 0.4×	266 0.7×	66	3.2k
Taizo Wada Japan	26	1.2k 0.8×	1.8k 3.0×	474 0.9×	647 1.5×	213 0.6×	139	3.5k
Frederick Schatz United States	45	4.0k 2.4×	756 1.3×	712 1.4×	526 1.2×	1.0k 2.8×	174	6.9k
Ryuta Nishikomori Japan	34	2.2k 1.3×	1.7k 2.8×	348 0.7×	491 1.1×	324 0.9×	148	4.0k
Christie P. Thomas United States	31	755 0.5×	1.2k 2.0×	272 0.5×	300 0.7×	144 0.4×	130	2.9k
Øystein Førre Norway	37	2.1k 1.3×	953 1.6×	249 0.5×	613 1.4×	277 0.8×	150	4.3k
Simon J. Clark United Kingdom	35	1.4k 0.9×	960 1.6×	101 0.2×	406 0.9×	353 1.0×	94	3.5k

Countries citing papers authored by Leman Yel

Since Specialization

Citations

This map shows the geographic impact of Leman Yel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leman Yel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leman Yel more than expected).

Fields of papers citing papers by Leman Yel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leman Yel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leman Yel. The network helps show where Leman Yel may publish in the future.

Co-authorship network of co-authors of Leman Yel

This figure shows the co-authorship network connecting the top 25 collaborators of Leman Yel. A scholar is included among the top collaborators of Leman Yel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leman Yel. Leman Yel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Patel, Niraj, Jolán E. Walter, Richard L. Wasserman, et al.. (2025). Efficacy, Safety, Tolerability, and Serum IgG Trough Levels of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in US Pediatric Patients with Primary Immunodeficiency Diseases. Journal of Clinical Immunology. 45(1). 81–81. 1 indexed citations

Čižnár, Peter, Marion Roderick, Miloš Jeseňák, et al.. (2024). fSCIG 10% in pediatric primary immunodeficiency diseases: a European post-authorization safety study. Allergy Asthma and Clinical Immunology. 20(1). 47–47. 1 indexed citations

Rubinstein, Arye, Donald McNeil, Niraj Patel, et al.. (2024). Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety Study. Journal of Clinical Immunology. 44(8). 181–181. 1 indexed citations

Li, Zhaoyang, et al.. (2024). Dose, exposure, and treatment regimen of intravenous immunoglobulin G in multifocal motor neuropathy. Frontiers in Neurology. 15. 1478419–1478419.

Kanegane, Hirokazu, Akifumi Endo, Satoshi Okada, et al.. (2024). Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study. PubMed. 4(1). ltae001–ltae001.

Li, Zhaoyang, et al.. (2024). Dose–exposure–efficacy response of intravenous immunoglobulin G 10% in multifocal motor neuropathy. Annals of Clinical and Translational Neurology. 11(8). 1977–1987. 1 indexed citations

Rubinstein, Arye, Donald McNeil, Niraj Patel, et al.. (2023). Long-term safety of facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases: final analysis from a post-authorization safety study conducted in the USA. Clinical Immunology. 250. 109424–109424.

Li, Zhaoyang, et al.. (2023). Evaluation of body weight–based dosing, alternative dosing regimens, and treatment interruptions for α1-proteinase inhibitors and implications on biochemical efficacy in patients with α1-antitrypsin deficiency. Pulmonary Pharmacology & Therapeutics. 83. 102265–102265.

Bril, Vera, Robert D. M. Hadden, Thomas H. Brannagan, et al.. (2023). Hyaluronidase‐facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE‐CIDP 1 randomized controlled trial. Journal of the Peripheral Nervous System. 28(3). 436–449. 14 indexed citations

10.

Borte, Michael, M Hrubiško, Karina Jahnz‐Różyk, et al.. (2022). Long-Term Safety of Facilitated Subcutaneous Immunoglobulin Treatment in Pregnant Women with Primary Immunodeficiency Diseases: Results from a Registry Study. Immunotherapy. 14(8). 609–616. 3 indexed citations

11.

Li, Zhaoyang, et al.. (2022). Pharmacokinetics and Biochemical Efficacy of an α1-Proteinase Inhibitor (Aralast NP) in α1-Antitrypsin Deficiency: a Cross-Product Retrospective Comparability Analysis. Pulmonary Therapy. 8(3). 311–326. 1 indexed citations

12.

Li, Zhaoyang, et al.. (2021). Population pharmacokinetic simulation of varied Immune Globulin Subcutaneous (Human), 20% solution (Ig20Gly) loading and maintenance dosing regimens in immunoglobulin-naïve patients with primary immunodeficiency diseases. International Immunopharmacology. 100. 108044–108044. 7 indexed citations

13.

Wasserman, Richard L., Isaac Melamed, Mark R. Stein, et al.. (2016). Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency. Journal of Clinical Immunology. 36(6). 571–582. 41 indexed citations

14.

Teschner, Wolfgang, et al.. (2013). Improving patient tolerability in immunoglobulin treatment: focus on stabilizer effects. Expert Review of Clinical Immunology. 9(6). 577–587. 7 indexed citations

15.

Zan, Hong, Jinsong Zhang, Egest J. Pone, et al.. (2010). Endonuclease G plays a role in immunoglobulin class switch DNA recombination by introducing double-strand breaks in switch regions. Molecular Immunology. 48(4). 610–622. 17 indexed citations

16.

Özgür, Tuba Turul, Leman Yel, Şule Yiğit, et al.. (2009). Lack of association between TLR4 polymorphism and severe gram-negative bacterial infection in neonates. TURKISH JOURNAL OF MEDICAL SCIENCES. 6 indexed citations

17.

Tavil, Betül, Özden Sanal, Tuba Turul, et al.. (2009). PARVOVIRUS B19-INDUCED PERSISTENT PURE RED CELL APLASIA IN A CHILD WITH T-CELL IMMUNODEFICIENCY. Pediatric Hematology and Oncology. 26(2). 63–68. 7 indexed citations

18.

Aggarwal, Sudeepta, et al.. (2000). TNF-α-induced apoptosis in neonatal lymphocytes: TNFRp55 expression and downstream pathways of apoptosis. Genes and Immunity. 1(4). 271–279. 25 indexed citations

19.

Sanal, Özden, Leman Yel, İlhan Tezcan, Fügen Ersoy, & İzzet Berkel. (1996). Homozygous C2 Deficiency: Association with Defective Alternative Pathway Function and Immunoglobulin Deficiency. International Archives of Allergy and Immunology. 110(2). 195–198. 6 indexed citations

20.

Sanal, Özden, Fügen Ersoy, Ayşe Metìn, et al.. (1995). Selective IgA deficiency with unusual features: Development of common variable immunodeficiency, Sjögren's syndrome, autoimmune hemolytic anemia and immune thrombocytopenic purpura. Pediatrics International. 37(4). 526–529. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact